Market Overview

Global Meningococcal Vaccines Market size was valued at around 3.47 billion in 2023 and is expected to reach a value of USD 5.76 billion by 2032, at a CAGR of 5.9% over the forecast period (2024–2032).

The Forecast Period of Meningococcal Vaccines Market

Among the most significant drivers likely to propel the market is the rising rate of meningitis. The Centres for Disease Control and Prevention (CDC) estimate that 1.2 million cases of bacterial meningitis will occur annually worldwide. Additionally, in the forecast period, the market will rise due to rising immunisation drives, rising awareness of infections, and rising research and development activities related to meningococcal vaccines.

The COVID-19 pandemic led to a decline in the overall market during 2020. Menactra, Menveo, Nimenrix, Trumenba, and Bexsero each saw a fall in net sales during 2020. The market, however, is expected to expand on a positive year-over-year basis of growth in 2022 as a result of growing government and regulatory activity to fight mounting cases of meningitis. For example, because of the extreme rate of meningitis in 2018, the Irish Ministry of Health approved MenACWY vaccine to be administered to thousands of teenagers in Ireland in May of 2019.

Government and non-governmental organizations, including the Meningitis Research Foundation of Canada, the National Meningitis Association (NMA), the Meningitis B Action Project, among others, are launching various campaigns and awareness initiatives. These organizations are promoting ongoing research and newer methods of preventing disease. So, in the upcoming years, these will be the drivers that will enhance the meningococcal vaccine market growth.

Market growth will be driven by the existence of non-profit institutions that sponsor research programs, provide education to medical professionals, and provide patients with information and assistance. For example, the National Foundation for Infectious Diseases (NFID) and DoSomething.Org launched the "Complete What's Missing Program" in August 2021. The program is intended to inform youth about the value of preventing meningococcal disease.

The market is set to expand because of the phase III vaccines in development and that are likely to be commercialized in the forecast period. For example, to evaluate and compare the safety, immunogenicity, and tolerability of PF-06886992, a pentavalent meningococcal candidate vaccine (MenABCWY), with licensed meningococcal vaccines among young adults and adolescents, phase III clinical trials were started in June 2020 by Pfizer, Inc. Further, there is a phase III clinical trial for Menactra, a conjugate vaccine by Serum Institute of India Pvt. Ltd.

Key Findings:

As Per WHO

• Worldwide in 2023, 14.5 million children were denied any vaccination – so-called zero-dose children.
• Immunization coverage with a third dose of diphtheria, tetanus toxoids, and pertussis vaccine (DTP3) was 84% in 2023.
• The percentage of children who were administered a first dose of measles vaccine was 83% in 2023, far less than the 86% level in 2019.
• Global immunization coverage for the initial dose of HPV vaccine among girls increased from 20% in 2022 to 27% in 2023.
• Yellow fever vaccine coverage in the risk countries is 50%, which is far less than the 80% recommended.

Market Drivers

Increasing Awareness of Meningococcal Disease Prevention

• The global market for meningococcal vaccination is driven chiefly by growing recognition of the devastating health consequences of meningococcal disease. Risk data regarding the meningococcal diseases meningitis and septicaemia have been widely promoted as a consequence in part of public health interventions, school-based education initiatives, and public education campaigns. Governments, NGOs, and physicians are underlining the use of vaccination as a powerful preventative tool, and it is focused on the most vulnerable populations, including children, teenagers, and tourists to epidemic areas. Global vaccination rates have risen because people are more aware.

Advancements in Vaccine Development

• Technological advances in vaccine technology are revolutionizing meningococcal disease prevention by providing wider protection and safer profiles. The availability of conjugate vaccines, conferring prolonged protection, and multivalent vaccines, protecting against two or more serogroups like A, C, W, Y, and B, has made immunization programs more effective. Further, new formulations with adjuvants to enhance immune response and thermostable vaccines for simplicity of distribution are finding recognition. These developments overcome current challenges like cold chain logistics and serogroup coverage limitations, further fuelling market growth.

Market Opportunities

Expansion of Immunization Programs in Low- and Middle-Income Countries

• Attempts to expand vaccine programs in impoverished areas pose a great opportunity for growth. Governments, assisted by international organizations such as WHO and Gavi, are aiming at strengthening immunization programs with additional funding, investments in infrastructure, and campaigns focused at community level. Such projects aim at the mitigation of unequal access to vaccines and decrease of meningococcal disease in the world.

Development of Thermostable and Enhanced Vaccines

• Production of thermostable and improved meningococcal vaccines is a promising prospect for market expansion. Thermostable formulations, which are heat-stable, ease storage and distribution, particularly in countries with weak cold chain facilities. In addition, improved vaccines that offer wider protection and fewer doses should boost demand, as they ease logistical issues and enhance immunization responses.

Market Restraining Factors

High Vaccine Costs

• The expense of meningococcal vaccines is the major deterrent factor, especially for low- and middle-income economies. Despite attempts by international organizations to reduce costs through subsidizing vaccines, widespread access remains unaffordable. The price tag of new-generation vaccines, adding to logistical cost for maintaining a cold chain, is challenging governments and healthcare units, thereby creating limitations for extensive reach of the immunization programs in low-income environments.

Segmentation Analysis

The market scope is segmented because of by Type, by Brand, by Age Group, By Serotype, By Sales Channel.

• By Type

Based on the Type of the market is segmented into Bivalent, Quadrivalent, Others.

The market is segmented into bivalent, quadrivalent, and others on the basis of type. Quadrivalent vaccinations accounted for the largest revenue share (52.3%) in 2023 due to popular brands such as Menactra, Menveo, and Nimenrix. In addition, the market is likely to increase when new vaccines that guard against meningococcal disease are licensed. For instance, Sanofi's MenQuadfi was licensed by the U.S. FDA in April 2020. In individuals two years and older, it is a quadrivalent meningococcal (Groups A, C, Y, and W) conjugate vaccine to prevent invasive meningococcal disease.

Second-highest market share was held by bivalent vaccinations because of the extensive use they have seen, their low affordability, and addition to many government programs worldwide. For instance, China's multistage meningococcal immunisation regimen consists of MenA and MenAC conjugate vaccines, both of which are given to the age group of 3-6 years for the MenAC vaccine and 6-18 months for the MenA vaccine. Besides these, monovalent, trivalent, and pentavalent vaccinations constitute the rest.

• By Brand

Based on the Brand of the market is segmented into Menactra, Menveo, Nimenrix, Trumenba, Bexsero, Others.

Bexsero contained the largest brand category revenue share of 33.8% during 2023 due to lower costs, reduced physician visits, and reduced dosing. With more than 40 countries holding licenses for it, such as New Zealand, Argentina, Chile, Australia, Israel, Uruguay, Turkey, and Europe, Bexsero is formulated for individuals two months of age and older. Also, segment share has augmented with the rise in the cases of vaccination of serotype B meningococcal disease. Also, funding for Bexsero shall commence from March 2023 for the 13- to 25-year age group along with immune infants up to the age of 12 months as part of the childhood immunisation program.

It is expected that within the forecast period, Trumenba would grow at the highest rate. The key drivers pushing the vaccine growth are increasing worldwide commercial approval and awareness of disease. The European Commission, for instance, approved Pfizer, Inc.'s Trumenba in May 2017 to protect individuals 10 years of age and older against IMD caused by MenB. Moreover, Trumenba was approved by the UK in July 2017 for individuals aged 10 years and above. The segment is thus anticipated to grow at the highest rate.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. On the revenue side, North America accounted for 57.8% of the market in 2023, trailed by Europe. High R&D investments and supportive government advice and encouragement are some of the drivers for the North American market. Furthermore, a good healthcare infrastructure and rising regional awareness drives are likely to propel market growth. A publicity campaign to increase the regional vaccination rate of the meningococcal vaccine is also being actively pursued by market participants. The ASK2BSure campaign, for example, was launched by GSK plc in August 2021 to encourage parents to talk to their doctors about their children's meningitis B immunization.

The Asia Pacific market was anticipated to expand significantly during the forecast period. Meningococcal vaccines are becoming more popular in the region on account of the rising number of children and the increased efforts by the government to check the spreading of the increasing cases of the disease. In addition, the non-profit organisations in the region enlighten people and inform medical authorities. Therefore, immunisation against meningococcal diseases is anticipated to be more popular.

List of Companies Profiled:

• Pfizer Inc.
• Sanofi
• Serum Institute of India Ltd.
• GSK plc.
• Merck & co., Inc.
• Walvax Biotechnology Co., Ltd.

Key Industry Developments

• In December 2023, the successful execution of Pfizer Inc.'s takeover of Seagen Inc., a multinational biotech company that discovers, develops, and commercializes life-changing cancer therapies, was announced.
• In November 2021, Merck branded as MSD, revealed the acquisition of Acceleron Pharma Inc had been successfully concluded.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Meningococcal Vaccines Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Meningococcal Vaccines Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Meningococcal Vaccines market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Meningococcal Vaccines. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Meningococcal Vaccines companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Meningococcal Vaccines Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Meningococcal Vaccines Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions:

• How much the global Meningococcal Vaccines Market valued?
• Which region has the largest share in 2024 for the global Meningococcal Vaccines Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Meningococcal Vaccines Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Meningococcal Vaccines Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: